API Drug Substance & Process Chemistry
Acquired from GSK in 2019 for €90M, this manufacturing site traces its roots to 1975 and doubled its lab and analytical capacity in a 2023 expansion, serving complex small-molecule API manufacturing for global pharmaceutical customers.